GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Approved

Tirzepatide

LY3298176

Company
Eli Lilly
Mechanism
dual GLP-1/GIP
Route
Injectable
Recruiting trials
95 recruiting
17.8% Placebo-adjusted weight loss · 72 weeks · Adults with obesity or overweight, without type 2 diabetes · SURMOUNT-1
Find a Clinical Trial Near Me

95 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Tirzepatide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05553093

    Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes

    Not yet reported Nanjing First Hospital, Nanjing Medical University 150 participants Est. completion 2027-10-31 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT05708859

    Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

    Not yet reported Matthew J. Budoff 120 participants Est. completion 2026-05 1 site
    Other conditions: Type II Diabetes, Atherosclerosis
    View official trial listing →
  • Recruiting NCT NCT05912621

    Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

    Not yet reported Stanford University 66 participants Est. completion 2029-12 1 site Stand-alone
    Other conditions: Obesity, Overweight and Obesity, Overweight
    View official trial listing →
  • Recruiting NCT NCT05933499

    Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

    Not yet reported Massachusetts General Hospital 63 participants Est. completion 2029-03-31 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT06143956

    A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

    Not yet reported Eli Lilly and Company 1481 participants Est. completion 2028-02 56 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Recruiting NCT NCT06191848

    Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

    Not yet reported University of Melbourne 352 participants Est. completion 2037-05 4 sites Stand-alone
    Osteoarthritis Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT06246799

    Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

    Not yet reported The University of Texas Health Science Center at San Antonio 256 participants Est. completion 2029-06-30 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT06374875

    Fibrosis Lessens After Metabolic Surgery

    Not yet reported The Cleveland Clinic 120 participants Est. completion 2029-12-31 22 sites
    MASLDMASH Other conditions: Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, Obesity
    View official trial listing →
  • Recruiting NCT NCT06431308

    Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events

    Not yet reported Ariel University 120 participants Est. completion 2026-03-30 3 sites
    Other conditions: Obesity; Drug
    View official trial listing →
  • Recruiting NCT NCT06439277

    A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

    Not yet reported Eli Lilly and Company 300 participants Est. completion 2030-12 69 sites Stand-alone
    Other conditions: Obesity, Weight Gain
    View official trial listing →
  • Recruiting NCT NCT06517212

    Tirzepatide Weight Loss for MRD+ Early Breast Cancer

    Not yet reported Baylor Research Institute 48 participants Est. completion 2030-12-31 1 site Stand-alone
    Other conditions: Breast Cancer, Breast Neoplasms, Breast Cancers
    View official trial listing →
  • Recruiting NCT NCT06518837

    Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

    Not yet reported Rutgers, The State University of New Jersey 40 participants Est. completion 2027-09-30 7 sites Stand-alone
    Other conditions: Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06575738

    Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents

    Not yet reported University of Colorado, Denver 40 participants Est. completion 2027-10-01 1 site Stand-alone
    Other conditions: Obesity, Adolescent Obesity, Body-Weight Trajectory, Weight Loss Trajectory, Bariatric Surgery, Anti-obesity Agents
    View official trial listing →
  • Recruiting NCT NCT06582875

    Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

    Not yet reported University of Colorado, Denver 126 participants Est. completion 2029-06-30 1 site Stand-alone
    Other conditions: Autosomal Dominant Polycystic Kidney, Obesity
    View official trial listing →
  • Recruiting NCT NCT06606821

    The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease

    Not yet reported Tina Vilsbøll 124 participants Est. completion 2028-08-01 3 sites Stand-alone
    Cardiovascular disease Other conditions: Coronary Microvascular Dysfunction, Overweight or Obesity, Stable Angina Pectoris
    View official trial listing →
  • Recruiting NCT NCT06630585

    GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes

    Not yet reported University of Bern 42 participants Est. completion 2026-06 3 sites Stand-alone
    Other conditions: Type 1 Diabetes (T1D)
    View official trial listing →
  • Recruiting NCT NCT06651177

    Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

    Not yet reported T. John Winhusen, PhD 310 participants Est. completion 2027-10-31 9 sites Stand-alone
    Substance use disorder
    View official trial listing →
  • Recruiting NCT NCT06657209

    Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

    Not yet reported Stanford University 104 participants Est. completion 2027-12-15 2 sites Stand-alone
    Type 2 diabetes Other conditions: Diabetes, Pre Diabetes
    View official trial listing →
  • Recruiting NCT NCT06700538

    A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

    Not yet reported, Not yet reported Arrowhead Pharmaceuticals 180 participants Est. completion 2028-01-17 7 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT06721507

    2024 Tirzepatide-Bariatric Surgery

    Not yet reported Marlene Starr 50 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Obesity and Obesity-related Medical Conditions, Bariatric Surgery
    View official trial listing →
  • Recruiting NCT NCT06727331

    Study of Tirzepatide for Recovery and Alcohol Use Management

    Not yet reported Brigham and Women's Hospital 20 participants Est. completion 2027-07-01 2 sites Stand-alone
    Alcohol use disorder
    View official trial listing →
  • Recruiting NCT NCT06734273

    Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss

    Not yet reported Nicholas Skertich 42 participants Est. completion 2028-09 1 site Stand-alone
    Other conditions: Obesity and Obesity-related Medical Conditions
    View official trial listing →
  • Recruiting NCT NCT06734312

    MAINTAIN (Mucosal AblatIoN Therapy After INcretins)

    Not yet reported Dr. Christopher McGowan 20 participants Est. completion 2026-06 2 sites Added to GLP-1
    Other conditions: Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism, GLP-1, Ablation Techniques
    View official trial listing →
  • Recruiting NCT NCT06751589

    A Study of a Weight Loss Intervention in People With Endometrial Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center 36 participants Est. completion 2027-12 7 sites Stand-alone
    Other conditions: Endometrial Cancer
    View official trial listing →
  • Recruiting NCT NCT06759701

    Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study

    Not yet reported M.D. Anderson Cancer Center 30 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Diabetes, Prostate Cancer
    View official trial listing →
  • Recruiting NCT NCT06774079

    Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

    Not yet reported University of Miami 24 participants Est. completion 2027-03-05 1 site Stand-alone
    Other conditions: Crohn Disease
    View official trial listing →
  • Recruiting NCT NCT06790160

    Study of Patients Being Treated With Anti-obesity Medication

    Texas Tech University 100 participants Est. completion 2027-12 1 site
    Other conditions: Obesity and Overweight
    View official trial listing →
  • Recruiting NCT NCT06802081

    TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

    Not yet reported The Cleveland Clinic 100 participants Est. completion 2027-06-01 1 site Stand-alone
    Other conditions: Atrial Fibrillation, Obesity
    View official trial listing →
  • Recruiting NCT NCT06811324

    Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

    Not yet reported The University of Texas Health Science Center at San Antonio 20 participants Est. completion 2027-06-01 1 site Stand-alone
    Other conditions: Obesity Prevention, Sarcopenia in Elderly, Cardiovascular Function, GLP - 1, Weight Loss
    View official trial listing →
  • Recruiting NCT NCT06820281

    Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes

    Not yet reported Victor Chang Cardiac Research Institute 44 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Recruiting NCT NCT06847399

    Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

    Not yet reported Johns Hopkins University 105 participants Est. completion 2027-12-01 1 site Stand-alone
    Other conditions: Obesity and Overweight, Binge Eating Disorder
    View official trial listing →
  • Recruiting NCT NCT06857942

    A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

    Not yet reported Eli Lilly and Company 200 participants Est. completion 2028-05 39 sites Stand-alone
    Other conditions: Psoriasis, Overweight or Obesity
    View official trial listing →
  • Recruiting NCT NCT06864026

    A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

    Not yet reported Eli Lilly and Company 200 participants Est. completion 2027-11 55 sites Stand-alone
    Other conditions: Psoriatic Arthritis, Overweight or Obesity
    View official trial listing →
  • Recruiting NCT NCT06885736

    LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy

    Not yet reported Dasman Diabetes Institute 232 participants Est. completion 2029-12-31 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT06897475

    A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Not yet reported Eli Lilly and Company 240 participants Est. completion 2027-01 60 sites
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT06901245

    Tirzepatide in PWS, HO and GNSO

    Not yet reported Grace Kim 36 participants Est. completion 2026-12 3 sites
    Other conditions: Prader-Willi Syndrome, Hypothalamic Obesity, Obesity/Therapy
    View official trial listing →
  • Recruiting NCT NCT06911203

    A Study of BGM0504 in Participants With Obesity

    Not yet reported BrightGene Bio-Medical Technology Co., Ltd. 90 participants Est. completion 2026-01-11 1 site
    Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT06934642

    Effect of Tirzepatide on Markers of MASLD in Patients With Obesity

    Not yet reported University of New Mexico 8 participants Est. completion 2026-10 1 site Stand-alone
    MASLD Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT06937086

    Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

    Not yet reported Eli Lilly and Company 350 participants Est. completion 2028-04 187 sites Stand-alone
    Other conditions: Ulcerative Colitis, Obesity or Overweight
    View official trial listing →
  • Recruiting NCT NCT06937099

    Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

    Not yet reported Eli Lilly and Company 290 participants Est. completion 2028-05 183 sites Stand-alone
    Other conditions: Crohn's Disease, Obesity or Overweight
    View official trial listing →
  • Recruiting NCT NCT06937203

    A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus

    Not yet reported, Not yet reported Arrowhead Pharmaceuticals 150 participants Est. completion 2027-02 8 sites Stand-alone
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT06939088

    Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder

    Not yet reported Anders Fink-Jensen, MD, DMSci 108 participants Est. completion 2028-12-31 2 sites Stand-alone
    Alcohol use disorder Other conditions: Alcohol Abuse/Dependence, Alcoholism, Schizophrenia Disorders, Schizophrenia and Disorders With Psychotic Features, Schizophrenia and Schizophrenia Spectrum Psychosis, Schizophrenia
    View official trial listing →
  • Recruiting NCT NCT06976853

    Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

    Not yet reported Washington University School of Medicine 60 participants Est. completion 2028-08 3 sites Stand-alone
    Other conditions: Crohn Disease (CD)
    View official trial listing →
  • Recruiting NCT NCT06994338

    Tirzepatide for Alcohol Use Disorder

    Not yet reported University of Southern California 42 participants Est. completion 2026-08-31 1 site Stand-alone
    Alcohol use disorder Other conditions: Obesity and Overweight, Alcohol
    View official trial listing →
  • Recruiting NCT NCT07042672

    Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity

    Haukeland University Hospital 80 participants Est. completion 2028-12-31 1 site
    Other conditions: Binge Eating Disorder Associated With Obesity, Binge Eating Disorder, Eating Disorder Binge, Eating Disorders, GLP-1, CBT, Obesity &Amp; Overweight
    View official trial listing →
  • Recruiting NCT NCT07046819

    Tirzepatide in MetALD

    Not yet reported National Institute on Alcohol Abuse and Alcoholism (NIAAA) 120 participants Est. completion 2027-07-30 1 site
    Alcohol use disorder Other conditions: Metabolic Alcohol-associated Liver Disease
    View official trial listing →
  • Recruiting NCT NCT07058155

    Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

    Not yet reported The Cleveland Clinic 70 participants Est. completion 2034-02-01 1 site
    Other conditions: Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
    View official trial listing →
  • Recruiting NCT NCT07065552

    Tirzepatide in Obesity-Driven Endometrial Cancer

    Not yet reported UNC Lineberger Comprehensive Cancer Center 20 participants Est. completion 2028-07 1 site Stand-alone
    Other conditions: Endometrial Cancer, Obesity
    View official trial listing →
  • Recruiting NCT NCT07091734

    Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024

    Not yet reported University of Michigan 32 participants Est. completion 2029-09 1 site Stand-alone
    Other conditions: Lipodystrophy, Partial
    View official trial listing →
  • Recruiting NCT NCT07094568

    Tirzepatide vs Liraglutide in Bone

    National and Kapodistrian University of Athens 72 participants Est. completion 2026-12-30 1 site
    Other conditions: Obesity (Disorder)
    View official trial listing →
  • Recruiting NCT NCT07095517

    Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors

    Not yet reported Massachusetts General Hospital 20 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Colorectal Cancer Prevention, Colorectal Adenoma
    View official trial listing →
  • Recruiting NCT NCT07096908

    Tirzepatide Use in People With Obesity and Type 1 Diabetes

    Not yet reported Dasman Diabetes Institute 60 participants Est. completion 2028-08-01 1 site Stand-alone
    Other conditions: Type1diabetes, Obesity
    View official trial listing →
  • Recruiting NCT NCT07107334

    A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia

    Not yet reported University of Florida 20 participants Est. completion 2029-11 1 site Stand-alone
    Other conditions: Endometrioid Endometrial Adenocarcinoma
    View official trial listing →
  • Recruiting NCT NCT07154719

    GLP-1R Actions on Muscle and the Skeleton

    Not yet reported Pennington Biomedical Research Center 50 participants Est. completion 2027-05-01 2 sites Stand-alone
    Other conditions: Musculoskeletal Abnormalities, Obesity, Sarcopenic Obesity, Osteoporosis, Drug Effect
    View official trial listing →
  • Recruiting NCT NCT07165028

    A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Not yet reported Eli Lilly and Company 4500 participants Est. completion 2032-08 563 sites Stand-alone
    MASLD
    View official trial listing →
  • Recruiting NCT NCT07191873

    Tirzepatide in Idiopathic Intracranial Hypertension Trial

    Not yet reported Duke University 60 participants Est. completion 2028-08 1 site
    Other conditions: Idiopathic Intracranial Hypertension (IIH)
    View official trial listing →
  • Recruiting NCT NCT07202247

    Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

    Not yet reported City of Hope Medical Center 60 participants Est. completion 2028-04-09 1 site Added to GLP-1
    Other conditions: Prostate Carcinoma, Recurrent Prostate Carcinoma
    View official trial listing →
  • Recruiting NCT NCT07213323

    Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment

    Not yet reported Hospices Civils de Lyon 50 participants Est. completion 2028-08-05 1 site Stand-alone
    Other conditions: Obesity &Amp; Overweight, Digestive Disorders
    View official trial listing →
  • Recruiting NCT NCT07218445

    The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

    Not yet reported Mayo Clinic 40 participants Est. completion 2027-09-18 1 site Stand-alone
    Other conditions: Obesity, Menopause Hot Flashes
    View official trial listing →
  • Recruiting NCT NCT07220473

    Tirzepatide to Slow Biological Aging

    Not yet reported The University of Texas Medical Branch, Galveston 90 participants Est. completion 2028-01 1 site
    Other conditions: Aging, LONGEVITY 1
    View official trial listing →
  • Recruiting NCT NCT07223242

    Tailored Exercise Training Study Among Adults With HFpEF

    Not yet reported, Not yet reported University of Texas Southwestern Medical Center 120 participants Est. completion 2026-12-30 1 site Stand-alone
    Heart failure Other conditions: Diabetic Cardiomyopathies
    View official trial listing →
  • Recruiting NCT NCT07228741

    Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

    Not yet reported St. Jude Children's Research Hospital 20 participants Est. completion 2028-11 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Obesity
    View official trial listing →
  • Recruiting NCT NCT07229170

    Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients

    San Raffaele Telematic University 150 participants Est. completion 2028-01-01 4 sites Stand-alone
    Other conditions: Obesity & Overweight, Taste Alterations, Weight Loss, Eating Behavior Changes
    View official trial listing →
  • Recruiting NCT NCT07245771

    Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity

    Not yet reported, Not yet reported Ikaria Bioscience Pty Ltd 104 participants Est. completion 2027-08-15 1 site Stand-alone
    Other conditions: Obesity &Amp; Overweight
    View official trial listing →
  • Recruiting NCT NCT07247084

    A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

    Not yet reported Eli Lilly and Company 3000 participants Est. completion 2032-07 30 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT07257484

    Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

    Not yet reported Weill Medical College of Cornell University 30 participants Est. completion 2028-02-25 1 site Stand-alone
    Other conditions: Obesity (Disorder), Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07284511

    A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

    Not yet reported, Not yet reported McGill University Health Centre/Research Institute of the McGill University Health Centre 105 participants Est. completion 2029-01 4 sites Stand-alone
    Other conditions: Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus
    View official trial listing →
  • Recruiting NCT NCT07293325

    Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity

    Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 66 participants Est. completion 2027-06-02 1 site Stand-alone
    Other conditions: Adults With Simple Obesity
    View official trial listing →
  • Recruiting NCT NCT07309094

    Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

    Cardenal Herrera University 250 participants Est. completion 2028-12-31 1 site
    Chronic kidney diseaseType 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT07326111

    A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese

    Not yet reported University of Bonn 198 participants Est. completion 2029-12 2 sites
    Other conditions: Polycystic Ovary Syndrome (PCOS), Obesity & Overweight
    View official trial listing →
  • Recruiting NCT NCT07364175

    A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults

    Not yet reported Cambridge University Hospitals NHS Foundation Trust 60 participants Est. completion 2029-01 1 site Stand-alone
    Other conditions: Hypertension, Obesity & Overweight
    View official trial listing →
  • Recruiting NCT NCT07373834

    Tirzepatide and Muscle Outcomes in Obesity

    Not yet reported University Medical Centre Ljubljana 30 participants Est. completion 2027-03 1 site Stand-alone
    Other conditions: Obesity (Disorder)
    View official trial listing →
  • Recruiting NCT NCT07387796

    Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation

    Not yet reported The University of Texas at Dallas 40 participants Est. completion 2029-02 1 site Stand-alone
    Substance use disorder Other conditions: Drug Discontinuation, Eating Behavior Changes, Tirzepatide
    View official trial listing →
  • Recruiting NCT NCT07398222

    Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study

    Hospital Israelita Albert Einstein 30 participants Est. completion 2026-03-20 1 site
    Other conditions: Full Stomach Status
    View official trial listing →
  • Recruiting NCT NCT07423247

    Tirzepatide (Spartina) in Obese Kidney Transplant Recipients

    Not yet reported Shahid Beheshti University of Medical Sciences 30 participants Est. completion 2026-09 1 site Stand-alone
    Other conditions: Tirzepatide
    View official trial listing →
  • Recruiting NCT NCT07443956

    Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis

    Not yet reported NHS Greater Glasgow and Clyde 45 participants Est. completion 2030-05 4 sites
    Other conditions: Psoriatic Arthritis (PsA), Obesity & Overweight
    View official trial listing →
  • Recruiting NCT NCT07457437

    Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment

    Not yet reported University of Exeter 60 participants Est. completion 2027-12-01 1 site
    Other conditions: Muscle Mass and Strength, Obesity & Overweight, Physical Function
    View official trial listing →
  • Recruiting NCT NCT07463846

    A Study to Evaluate ALN-2232 in Participants With Obesity

    Not yet reported, Not yet reported Alnylam Pharmaceuticals 156 participants Est. completion 2028-03-02 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT07481747

    Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

    Not yet reported Hudson Biotech 2539 participants Est. completion 2028-03-17 1 site Stand-alone
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT07521631

    Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes

    Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 372 participants Est. completion 2027-07-23 1 site
    Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT07527910

    A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

    Not yet reported Regeneron Pharmaceuticals 204 participants Est. completion 2030-03-15 6 sites Stand-alone
    MASLD
    View official trial listing →
  • Recruiting NCT NCT07554638

    Incretin Therapies in Obesity-related HFpEF

    Not yet reported Columbia University 50 participants Est. completion 2030-04 1 site Stand-alone
    Heart failure Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT07559500

    Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)

    Not yet reported National Institute on Alcohol Abuse and Alcoholism (NIAAA) 176 participants Est. completion 2031-12-31 1 site
    Alcohol use disorder
    View official trial listing →
  • Recruiting NCT NCT07573163

    Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

    Not yet reported Alaa Sada 34 participants Est. completion 2028-12-31 1 site
    Other conditions: Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; Status
    View official trial listing →
  • Recruiting NCT NCT07574723

    Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity

    Not yet reported Dasman Diabetes Institute 68 participants Est. completion 2029-12-31 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT07588438

    Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.

    Not yet reported Las Rías Medical Center 160 participants Est. completion 2027-08-10 1 site Stand-alone
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT07589322

    Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs

    Not yet reported Tri-Service General Hospital (TSGH) 120 participants Est. completion 2029-09-30 1 site
    Metabolic syndrome
    View official trial listing →
  • Recruiting NCT NCT07602699

    Multi-Site Trial of Tirzepatide for Smoking Cessation

    Not yet reported University of Southern California 300 participants Est. completion 2028-09 4 sites Stand-alone
    Other conditions: Smoking Cessation, Smoking Behaviors
    View official trial listing →
  • Recruiting NCT NCT07619989

    Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists

    Not yet reported The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 24 participants Est. completion 2027-09-01 1 site Stand-alone
    Other conditions: Obesity & Overweight
    View official trial listing →
  • Recruiting NCT NCT07633639

    GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity

    Not yet reported China-Japan Friendship Hospital 200 participants Est. completion 2028-05-01 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT07650149

    Genetic, Microbiological and Behavioral Factors in Obesity

    Jan Kochanowski University 200 participants Est. completion 2028-05 2 sites
    Other conditions: Obesity & Overweight, Obesity, Genetics
    View official trial listing →
  • Recruiting NCT NCT07653412

    Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.

    National and Kapodistrian University of Athens 220 participants Est. completion 2027-06-30 1 site
    Other conditions: Obesity (Disorder), Anti-obesity Agents, Precision Medicine
    View official trial listing →
  • Recruiting NCT NCT07702461

    Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

    Ohio State University 300 participants Est. completion 2027-01 1 site
    Other conditions: Obesity & Overweight, Diabetes (DM)
    View official trial listing →
  • Recruiting NCT NCT07720414

    Effects of GLP-1 RAs on Human Lactation Outcomes

    University of Colorado, Denver 18 participants Est. completion 2028-06 1 site
    Other conditions: Lactation, Weight Loss
    View official trial listing →
  • Recruiting NCT NCT07740291

    Tirzepatide Impact Assessment Study

    Not yet reported Texas Tech University 27 participants Est. completion 2026-12-07 1 site Stand-alone
    Other conditions: Obesity & Overweight, Cardiometabolic Health Indicators, Addiction, Eating Disorders, Mental Health
    View official trial listing →
  • Completed NCT NCT02759107

    A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

    Not yet reported Eli Lilly and Company 142 participants Est. completion 2017-06-26 2 sites Stand-alone
    Type 2 diabetes Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT03131687

    A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

    Not yet reported Eli Lilly and Company 318 participants Est. completion 2018-08-01 49 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03311724

    A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

    Not yet reported Eli Lilly and Company 111 participants Est. completion 2018-04-24 13 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03322631

    A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes

    Not yet reported Eli Lilly and Company 48 participants Est. completion 2018-11-28 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03375463

    A Study of Tirzepatide (LY3298176) in Healthy Participants

    Not yet reported Eli Lilly and Company 52 participants Est. completion 2018-12-27 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT03482024

    A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function

    Not yet reported Eli Lilly and Company 45 participants Est. completion 2019-08-19 4 sites Stand-alone
    Other conditions: Renal Insufficiency, End Stage Renal Disease
    View official trial listing →
  • Completed NCT NCT03730662

    A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

    Not yet reported Eli Lilly and Company 2002 participants Est. completion 2021-04-22 216 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03861039

    A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

    Not yet reported Eli Lilly and Company 443 participants Est. completion 2021-02-16 34 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03861052

    A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

    Not yet reported Eli Lilly and Company 636 participants Est. completion 2021-03-31 46 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03882970

    A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

    Not yet reported Eli Lilly and Company 1444 participants Est. completion 2021-01-04 122 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03940742

    A Study of Tirzepatide in Participants With Impaired Liver Function

    Not yet reported Eli Lilly and Company 32 participants Est. completion 2020-09-22 3 sites Stand-alone
    Other conditions: Hepatic Insufficiency
    View official trial listing →
  • Completed NCT NCT03951753

    A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)

    Not yet reported Eli Lilly and Company 117 participants Est. completion 2021-04-08 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03954834

    A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

    Not yet reported Eli Lilly and Company 478 participants Est. completion 2020-10-28 53 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03987919

    A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

    Not yet reported Eli Lilly and Company 1879 participants Est. completion 2021-02-15 127 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04004988

    A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants

    Not yet reported Eli Lilly and Company 47 participants Est. completion 2019-12-16 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT04039503

    A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

    Not yet reported Eli Lilly and Company 475 participants Est. completion 2021-01-13 48 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04050553

    A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus

    Not yet reported Eli Lilly and Company 42 participants Est. completion 2022-01-25 1 site Stand-alone
    Type 2 diabetes Other conditions: Hypoglycemia
    View official trial listing →
  • Completed NCT NCT04050670

    A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes

    Not yet reported Eli Lilly and Company 54 participants Est. completion 2020-04-03 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT04081337

    A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

    Not yet reported Eli Lilly and Company 55 participants Est. completion 2022-05-26 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT04093752

    A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)

    Not yet reported Eli Lilly and Company 917 participants Est. completion 2021-11-24 67 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04166773

    A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

    Not yet reported Eli Lilly and Company 190 participants Est. completion 2024-01-10 112 sites Stand-alone
    MASH
    View official trial listing →
  • Completed NCT NCT04172987

    A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants

    Not yet reported Eli Lilly and Company 40 participants Est. completion 2021-02-09 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT04184622

    A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

    Not yet reported Eli Lilly and Company 2539 participants Est. completion 2024-07-06 118 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT04235959

    A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus

    Not yet reported Eli Lilly and Company 24 participants Est. completion 2021-08-17 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04255433

    A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

    Not yet reported Eli Lilly and Company 13299 participants Est. completion 2025-06-12 635 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04311411

    A Study of Tirzepatide in Overweight and Very Overweight Participants

    Not yet reported Eli Lilly and Company 114 participants Est. completion 2022-12-16 3 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT04311424

    Study of Tirzepatide in Healthy Participants

    Not yet reported Eli Lilly and Company 6 participants Est. completion 2020-10-02 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT04407234

    A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide

    Not yet reported Eli Lilly and Company 36 participants Est. completion 2021-01-07 1 site Stand-alone
    Type 2 diabetes Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT04537923

    A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

    Not yet reported Eli Lilly and Company 1428 participants Est. completion 2022-11-01 135 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04657003

    A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

    Not yet reported Eli Lilly and Company 938 participants Est. completion 2023-04-10 75 sites Stand-alone
    Type 2 diabetes Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT04657016

    A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

    Not yet reported Eli Lilly and Company 579 participants Est. completion 2023-05-12 65 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT04660643

    A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss

    Not yet reported Eli Lilly and Company 783 participants Est. completion 2023-05-18 70 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT04844918

    A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease

    Not yet reported Eli Lilly and Company 267 participants Est. completion 2023-06-24 18 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT04847557

    A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

    Not yet reported Eli Lilly and Company 731 participants Est. completion 2024-07-02 146 sites Stand-alone
    Heart failure Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT05024032

    A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)

    Not yet reported Eli Lilly and Company 210 participants Est. completion 2022-12-27 29 sites Stand-alone
    Other conditions: Obesity, Overweight, Metabolism and Nutrition Disorder
    View official trial listing →
  • Completed NCT NCT05260021

    A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

    Not yet reported Eli Lilly and Company 99 participants Est. completion 2025-01-28 51 sites Stand-alone
    Type 2 diabetes Other conditions: Diabetes Mellitus, Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
    View official trial listing →
  • Completed NCT NCT05412004

    Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

    Not yet reported Eli Lilly and Company 469 participants Est. completion 2024-03-29 58 sites Stand-alone
    Obstructive sleep apnea Other conditions: Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT05433584

    A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

    Not yet reported Eli Lilly and Company 780 participants Est. completion 2027-11 90 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT05536804

    A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

    Not yet reported Eli Lilly and Company 140 participants Est. completion 2026-10 27 sites Stand-alone
    Chronic kidney diseaseType 2 diabetes Other conditions: Overweight, Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT05556512

    A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

    Not yet reported Eli Lilly and Company 15374 participants Est. completion 2027-10 671 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT05564039

    A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

    Not yet reported Eli Lilly and Company 282 participants Est. completion 2024-08-12 38 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05582096

    A Study of LY3457263 in Obese Participants

    Not yet reported Eli Lilly and Company 38 participants Est. completion 2023-06-08 1 site Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Status unknown NCT NCT05659368

    Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1

    Not yet reported Ospedale San Raffaele 10 participants Est. completion 2024-12 1 site Stand-alone
    Other conditions: Wolfram Syndrome
    View official trial listing →
  • Completed NCT NCT05691712

    A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

    Not yet reported Eli Lilly and Company 257 participants Est. completion 2024-07-01 25 sites Stand-alone
    Other conditions: Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
    View official trial listing →
  • Completed NCT NCT05696847

    A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity

    Not yet reported Eli Lilly and Company 28 participants Est. completion 2025-01-16 3 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT05706506

    A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

    Not yet reported Eli Lilly and Company 152 participants Est. completion 2023-10-31 32 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT05751720

    Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue

    Not yet reported, Not yet reported Dr Adnan Agha 30 participants Est. completion 2025-02 1 site Stand-alone
    Type 2 diabetes Other conditions: Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Liver Fat
    View official trial listing →
  • Active, not recruiting NCT NCT05756764

    Anti-obesity Pharmacotherapy and Inflammation

    Louisiana State University Health Sciences Center in New Orleans 30 participants Est. completion 2026-02-20 2 sites
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT05766358

    Role Of Metabolic Adaptation In Weight Regain

    Pennington Biomedical Research Center 27 participants Est. completion 2024-05-24 1 site
    Other conditions: Weight Loss, Weight Gain, Obesity
    View official trial listing →
  • Completed NCT NCT05810597

    A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices

    Not yet reported Eli Lilly and Company 65 participants Est. completion 2023-07-17 3 sites Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Withdrawn NCT NCT05812183

    Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity

    Not yet reported University of California, Los Angeles Est. completion 2025-02-12 Stand-alone
    Other conditions: Dyspnea, Quality of Life
    View official trial listing →
  • Active, not recruiting NCT NCT05822544

    Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes

    Not yet reported OrsoBio, Inc 564 participants Est. completion 2027-01 4 sites Stand-alone
    Type 2 diabetes Other conditions: Healthy Subjects, Obesity
    View official trial listing →
  • Completed NCT NCT05822830

    A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

    Not yet reported Eli Lilly and Company 751 participants Est. completion 2024-11-13 32 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT05963022

    A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)

    Not yet reported Eli Lilly and Company 206 participants Est. completion 2024-10-09 28 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05978713

    A Study of Tirzepatide (LY3298176) in Healthy Lactating Females

    Not yet reported Eli Lilly and Company 11 participants Est. completion 2024-03-12 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Status unknown NCT NCT05990374

    Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years

    Not yet reported Nanjing First Hospital, Nanjing Medical University 100 participants Est. completion 2024-01-01 1 site
    Other conditions: Diabetes
    View official trial listing →
  • Withdrawn NCT NCT06009653

    Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity

    Not yet reported Washington University School of Medicine Est. completion 2024-05-29 1 site Stand-alone
    Other conditions: Obesity, Metabolic Disease
    View official trial listing →
  • Active, not recruiting NCT NCT06037252

    A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

    Not yet reported Eli Lilly and Company 414 participants Est. completion 2026-10 40 sites Stand-alone
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT06047548

    A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

    Not yet reported Eli Lilly and Company 441 participants Est. completion 2026-01-20 20 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT06073184

    Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium

    Not yet reported University Health Network, Toronto 71 participants Est. completion 2032-02 Stand-alone
    Other conditions: Endometrial Cancer, Atypical Hyperplasia
    View official trial listing →
  • Active, not recruiting NCT NCT06075667

    A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

    Not yet reported Eli Lilly and Company 160 participants Est. completion 2029-07 33 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT06131437

    A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

    Not yet reported Novo Nordisk A/S 809 participants Est. completion 2026-01-09 46 sites
    Other conditions: Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT06162715

    GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

    Not yet reported, Not yet reported Vanderbilt University Medical Center 30 participants Est. completion 2027-12-01 1 site Stand-alone
    Other conditions: Severe Obesity, Obesity, BMI Greater Than 30
    View official trial listing →
  • Not yet recruiting NCT NCT06180616

    Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity

    Not yet reported Royal North Shore Hospital 40 participants Est. completion 2028-12 Stand-alone
    Other conditions: Type 1 Diabetes Mellitus, Overweight and Obesity
    View official trial listing →
  • Completed NCT NCT06221969

    A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

    Not yet reported Novo Nordisk A/S 1024 participants Est. completion 2026-04-06 197 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06297616

    A Study of LY3841136 in Japanese Participants With Obesity or Overweight

    Not yet reported Eli Lilly and Company 128 participants Est. completion 2025-11-21 3 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Status unknown NCT NCT06301256

    Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa

    Not yet reported Florida Academic Centers Research and Education, LLC 20 participants Est. completion 2025-03-11
    Other conditions: Hidradenitis Suppurativa
    View official trial listing →
  • Completed NCT NCT06326047

    A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

    Not yet reported Novo Nordisk A/S 299 participants Est. completion 2025-10-13 110 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06326060

    A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

    Not yet reported Novo Nordisk A/S 354 participants Est. completion 2025-05-01 70 sites
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT06345066

    A Study of LY3841136 in Overweight and Obese Participants

    Not yet reported Eli Lilly and Company 96 participants Est. completion 2025-09-29 3 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Withdrawn NCT NCT06354101

    The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.

    CorEvitas Est. completion 2023-07-01
    Other conditions: Metabolic Health
    View official trial listing →
  • Completed NCT NCT06373146

    A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

    Not yet reported Eli Lilly and Company 392 participants Est. completion 2026-04-02 17 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT06400615

    Study That Tests AD109 in Patients Taking GLP-1 Drugs

    Not yet reported Apnimed 40 participants Est. completion 2024-12-26 4 sites
    Obstructive sleep apnea
    View official trial listing →
  • Completed NCT NCT06445075

    Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

    Not yet reported Scholar Rock, Inc. 102 participants Est. completion 2025-06-17 7 sites Stand-alone
    Other conditions: Overweight and Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT06467604

    CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users

    University of California, Davis 7 participants Est. completion 2027-04-01 1 site
    Other conditions: Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT06484114

    Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide

    Not yet reported Fractyl Health Inc. 315 participants Est. completion 2027-02-26 32 sites
    Other conditions: Obesity, Weight Change Trajectory, Weight Change, Body
    View official trial listing →
  • Completed NCT NCT06485089

    Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers

    University of Kansas Medical Center 25 participants Est. completion 2026-03-25 2 sites
    Other conditions: Obesity, Breast Cancer Risk
    View official trial listing →
  • Terminated NCT NCT06515418

    Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

    Not yet reported BioAge Labs, Inc. 204 participants Est. completion 2025-02-12 14 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT06533527

    Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy

    Not yet reported The Cleveland Clinic 69 participants Est. completion 2025-05-20 2 sites
    Type 2 diabetes Other conditions: Obesity, Gastroparesis
    View official trial listing →
  • Completed NCT NCT06534411

    A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

    Not yet reported Novo Nordisk A/S 1023 participants Est. completion 2026-07-09 163 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT06565611

    A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity

    Not yet reported Palatin Technologies, Inc 108 participants Est. completion 2025-03-31 4 sites
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT06584916

    A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

    Not yet reported Eli Lilly and Company 376 participants Est. completion 2025-11-21 29 sites
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT06588283

    Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

    Not yet reported Eli Lilly and Company 281 participants Est. completion 2026-06-01 72 sites Stand-alone
    Other conditions: Psoriasis, Obesity
    View official trial listing →
  • Completed NCT NCT06588296

    Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

    Not yet reported Eli Lilly and Company 279 participants Est. completion 2026-04-23 86 sites Stand-alone
    Other conditions: Psoriatic Arthritis, Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT06603571

    A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

    Not yet reported Eli Lilly and Company 367 participants Est. completion 2026-08 52 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT06605703

    A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)

    Not yet reported WW International Inc 226 participants Est. completion 2026-02-05 1 site
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT06635057

    A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan

    Not yet reported Eli Lilly and Company 166 participants Est. completion 2026-04-15 29 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06640972

    Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists

    Not yet reported Response Pharmaceuticals 68 participants Est. completion 2025-05-13 1 site
    Other conditions: Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
    View official trial listing →
  • Active, not recruiting NCT NCT06643728

    A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

    Not yet reported Eli Lilly and Company 252 participants Est. completion 2027-01 12 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT06648031

    Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants

    Not yet reported Lexaria Bioscience Corp. 148 participants Est. completion 2025-07-31 7 sites Stand-alone
    Other conditions: Type2diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT06662383

    A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

    Not yet reported Eli Lilly and Company 800 participants Est. completion 2026-12 65 sites
    Other conditions: Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT06732245

    Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

    Not yet reported Biomed Industries, Inc. 224 participants Est. completion 2027-12-15 17 sites Stand-alone
    Other conditions: Obesity and Overweight
    View official trial listing →
  • Completed NCT NCT06737042

    Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

    Not yet reported Gan and Lee Pharmaceuticals, USA 326 participants Est. completion 2026-02-27 20 sites
    Other conditions: Obesity and Overweight
    View official trial listing →
  • Active, not recruiting NCT NCT06745128

    Tirzepatide for Obesity and Meth Use Disorder

    Not yet reported University of Texas Southwestern Medical Center 45 participants Est. completion 2026-03-31 1 site Stand-alone
    Other conditions: Obesity, Methamphetamine Use Disorder
    View official trial listing →
  • Completed NCT NCT06761703

    A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss

    Amgen 200 participants Est. completion 2025-01-06 1 site
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT06779929

    Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

    Brigham and Women's Hospital 70000 participants Est. completion 2026-03-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT06801015

    Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

    Not yet reported Mayo Clinic 30 participants Est. completion 2028-03-31 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT06803888

    Bariatric Surgery vs. Semaglutide vs. Tirzepatide

    Not yet reported Ali Aminian 140 participants Est. completion 2027-12-01 1 site
    Other conditions: Obesity and Obesity-related Medical Conditions
    View official trial listing →
  • Not yet recruiting NCT NCT06856928

    Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.

    University of Colorado, Denver 16 participants Est. completion 2027-12
    Other conditions: Obesity; Drug
    View official trial listing →
  • Active, not recruiting NCT NCT06861439

    GLP-1s to Enhance Lasting Optimal Weight

    Not yet reported Wake Forest University Health Sciences 40 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT06890611

    A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

    Not yet reported Eli Lilly and Company 125 participants Est. completion 2025-09-26 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT06893211

    Effect of Tirzepatide on Brown Adipose Tissue in Obesity

    Not yet reported University Medical Centre Ljubljana 34 participants Est. completion 2025-12-20 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Withdrawn NCT NCT06901349

    A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

    Not yet reported Eli Lilly and Company Est. completion 2025-06-10 50 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT06914141

    Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction

    Brigham and Women's Hospital 28118 participants Est. completion 2025-06-01 1 site
    Type 2 diabetesHeart failure
    View official trial listing →
  • Completed NCT NCT06914154

    Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data

    Brigham and Women's Hospital 11265 participants Est. completion 2025-06-01 1 site
    Type 2 diabetesHeart failure
    View official trial listing →
  • Active, not recruiting NCT NCT06914895

    A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

    Not yet reported Eli Lilly and Company 905 participants Est. completion 2026-12 146 sites Stand-alone
    Other conditions: Type 1 Diabetes, Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT06916065

    A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

    Not yet reported Eli Lilly and Company 188 participants Est. completion 2026-01-19 3 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT06918405

    Efficacy and Safety of Tirzepatide for Weight Management

    Not yet reported Chittagong Medical College 440 participants Est. completion 2026-06-30 1 site Stand-alone
    Other conditions: Obesity and Obesity-related Medical Conditions
    View official trial listing →
  • Completed NCT NCT06935838

    Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV

    Not yet reported University of Hawaii 12 participants Est. completion 2026-06-02 1 site Stand-alone
    Other conditions: Obesity and Overweight, HIV, Chronic Inflammation
    View official trial listing →
  • Not yet recruiting NCT NCT06950684

    Impact of Protein Supplementation and Resistance Training on Body Composition, Functional Parameters, Metabolic Adaptation, and Nitrogen Balance in Adults Aged 45 Years and Older With Overweight or Obesity Receiving Incretin-based Medications

    Not yet reported Assuta Medical Center 180 participants Est. completion 2028-07-01
    Other conditions: Obesity, Overweight (BMI > 25), Weight Loss
    View official trial listing →
  • Active, not recruiting NCT NCT06962280

    A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

    Not yet reported Eli Lilly and Company 465 participants Est. completion 2027-07 79 sites Stand-alone
    Other conditions: Type 1 Diabetes, Obesity, Overweight
    View official trial listing →
  • Active, not recruiting NCT NCT06965413

    A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

    Not yet reported Hoffmann-La Roche 285 participants Est. completion 2027-03-31 35 sites Stand-alone
    Other conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity
    View official trial listing →
  • Active, not recruiting NCT NCT06980623

    Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

    Brigham and Women's Hospital 26000 participants Est. completion 2026-10-01 1 site
    Type 2 diabetesHeart failure
    View official trial listing →
  • Active, not recruiting NCT NCT07000955

    Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity

    Not yet reported, Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 98 participants Est. completion 2027-05-14 1 site
    Other conditions: Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07027969

    Metabolic Surgery for Atrial Fibrillation Elimination

    Not yet reported Ali Aminian 100 participants Est. completion 2030-03-31 1 site
    Other conditions: Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
    View official trial listing →
  • Enrolling by invitation NCT NCT07041983

    24-h Energy Expenditure and Anti-obesity Medication

    University of Pisa 30 participants Est. completion 2026-12-01 1 site
    Other conditions: Obesity
    View official trial listing →
  • Enrolling by invitation NCT NCT07057310

    Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

    Not yet reported Mayo Clinic 30 participants Est. completion 2027-03-31 1 site Stand-alone
    Other conditions: Obesity, Menopause
    View official trial listing →
  • Not yet recruiting NCT NCT07078838

    Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer

    Not yet reported UNC Lineberger Comprehensive Cancer Center 40 participants Est. completion 2029-03 1 site Stand-alone
    Other conditions: Endometrial Cancer, Endometrial Intraepithelial Neoplasia, Grade 1 Endometrial Endometrioid Carcinoma
    View official trial listing →
  • Completed NCT NCT07088718

    Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

    Brigham and Women's Hospital 44671 participants Est. completion 2025-07-30 1 site
    Type 2 diabetes Other conditions: Major Adverse Cardiac Events, Cardiovascular (CV) Risk
    View official trial listing →
  • Completed NCT NCT07096063

    Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

    Brigham and Women's Hospital 887132 participants Est. completion 2025-07-15 1 site
    Type 2 diabetes Other conditions: Overweight, Cardiovascular (CV) Risk
    View official trial listing →
  • Not yet recruiting NCT NCT07099742

    Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)

    Dr. Md. Alimur Reza 364 participants Est. completion 2026-07 3 sites
    Other conditions: Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT07115069

    Comparison of Body Composition Changes With Weight Loss Interventions

    Vanderbilt University Medical Center 60 participants Est. completion 2027-12 1 site
    Other conditions: Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT07128082

    The Long COVID Treatment Trial

    Not yet reported Scripps Translational Science Institute 1000 participants Est. completion 2026-12 1 site
    Other conditions: Long COVID
    View official trial listing →
  • Not yet recruiting NCT NCT07156331

    Research on Effects of Drugs on Body Composition and Function With Imaging in Diabetes

    Kristin Clemens 20 participants Est. completion 2027-12-31
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07176663

    Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure

    Not yet reported Shahid Beheshti University of Medical Sciences 15 participants Est. completion 2026-05-01 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07179120

    Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health

    Not yet reported First Affiliated Hospital of Wenzhou Medical University 180 participants Est. completion 2027-01-02 Stand-alone
    Other conditions: Obesity-related Male Infertility
    View official trial listing →
  • Active, not recruiting NCT NCT07188545

    Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

    Ohio State University 23280000 participants Est. completion 2029-06-30 1 site
    Metabolic syndrome
    View official trial listing →
  • Completed NCT NCT07203677

    Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)

    Brigham and Women's Hospital 49065 participants Est. completion 2025-10-15 1 site
    Type 2 diabetesCardiovascular disease
    View official trial listing →
  • Completed NCT NCT07262762

    Spartina® (Tirzepatide) Effectiveness and Safety Evaluation

    Cinnagen 175 participants Est. completion 2026-07-05 14 sites
    Other conditions: Obesity & Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07265752

    Tirzepatide for the Treatment of Cannabis Use Disorder

    Not yet reported Brigham and Women's Hospital 6 participants Est. completion 2028-06-30 Stand-alone
    Other conditions: Cannabis Use Disorder
    View official trial listing →
  • Not yet recruiting NCT NCT07292519

    Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)

    Not yet reported South West Sydney Local Health District 46 participants Est. completion 2028-01-15 1 site Stand-alone
    Alcohol use disorder Other conditions: Overweight or Obese, Comorbidities and Coexisting Conditions
    View official trial listing →
  • Not yet recruiting NCT NCT07298915

    The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)

    Not yet reported University of Virginia 24 participants Est. completion 2027-06 1 site Stand-alone
    Other conditions: Obesity & Overweight
    View official trial listing →
  • Active, not recruiting NCT NCT07299084

    A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus

    Not yet reported Eli Lilly and Company 40 participants Est. completion 2026-11 1 site Stand-alone
    Type 2 diabetes Other conditions: Overweight, Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT07303556

    Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs

    Not yet reported Nazarbayev University 120 participants Est. completion 2026-11-01 1 site Stand-alone
    Heart failure Other conditions: Diabete Type 2, Arterial Hypertension
    View official trial listing →
  • Not yet recruiting NCT NCT07319975

    Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity

    Not yet reported Istanbul Galata University 48 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07349641

    A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

    Not yet reported National Cancer Institute (NCI) 55 participants Est. completion 2030-10-31 3 sites Stand-alone
    Other conditions: Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
    View official trial listing →
  • Not yet recruiting NCT NCT07354880

    Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease

    Not yet reported University Medical Centre Ljubljana 30 participants Est. completion 2027-12-31
    Other conditions: Obesity & Overweight, Adult Congenital Heart Disease
    View official trial listing →
  • Completed NCT NCT07368855

    GLP-1 Medicines and Mental Health Changes

    Not yet reported University of California, San Diego 90 participants Est. completion 2025-07-01 1 site
    Other conditions: Obesity, Depression, GLP-1
    View official trial listing →
  • Not yet recruiting NCT NCT07382024

    Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation

    Not yet reported National Taiwan University Hospital 200 participants Est. completion 2028-07-31 1 site
    Other conditions: Atrial Fibrillation Ablation, Persistent Atrial Fibrillation, Obesity & Overweight
    View official trial listing →
  • Completed NCT NCT07382180

    Real-World Tirzepatide Therapy in Post-Bariatric Weight Regain and Preoperative Obesity Patients

    Azienda Sanitaria Locale Napoli 2 Nord 254 participants Est. completion 2026-01-18 1 site
    Other conditions: Obesity & Overweight, Weight Regain, Obesity, Morbid
    View official trial listing →
  • Not yet recruiting NCT NCT07382388

    A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis

    Peking University Third Hospital 70 participants Est. completion 2027-12-31
    Other conditions: Psoriasis
    View official trial listing →
  • Completed NCT NCT07417618

    INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)

    Brigham and Women's Hospital 60000 participants Est. completion 2026-06-19 1 site
    Type 2 diabetesCardiovascular disease Other conditions: Overweight
    View official trial listing →
  • Active, not recruiting NCT NCT07438444

    A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity

    Not yet reported Eli Lilly and Company 344 participants Est. completion 2027-07 21 sites Stand-alone
    Type 2 diabetes Other conditions: Obesity, Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07444073

    Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock

    National University of Singapore 440 participants Est. completion 2027-12-31 2 sites
    Other conditions: Aging, Obesity & Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07468552

    Trial of Tirzepatide for the Treatment of Cannabis Use Disorder

    Not yet reported National Institute on Drug Abuse (NIDA) 100 participants Est. completion 2028-11-15 Stand-alone
    Other conditions: Cannabis Use Disorder
    View official trial listing →
  • Not yet recruiting NCT NCT07483801

    DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies

    Not yet reported Cambridge University Hospitals NHS Foundation Trust 112 participants Est. completion 2028-04 1 site Mixed
    Cardiovascular disease
    View official trial listing →
  • Not yet recruiting NCT NCT07492563

    Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay

    LABORATORIOS INDUFAR 300 participants Est. completion 2027-10 1 site
    Type 2 diabetes Other conditions: Obesity, Overweight With Comorbidities
    View official trial listing →
  • Not yet recruiting NCT NCT07504172

    Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity

    Radboud University Medical Center 1700 participants Est. completion 2026-08-01 10 sites
    Other conditions: Overweight , Obesity, Obesity (Disorder)
    View official trial listing →
  • Not yet recruiting NCT NCT07555730

    AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)

    Not yet reported Huazhong University of Science and Technology 400 participants Est. completion 2028-09-30 1 site
    Type 2 diabetes Other conditions: Weight Loss Maintenance
    View official trial listing →
  • Not yet recruiting NCT NCT07567378

    CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry

    JULIO GRANADOS MONTIEL 30 participants Est. completion 2029-05 1 site
    Type 2 diabetesMetabolic syndromeHeart failureCardiovascular disease Other conditions: Psoriatic Arthritis, Osteoarthitis, Knee, Diabetes (DM), Obesity (Disorder), Insulin Resistance Syndrome, Preserved Ejection Fraction, Atrial Fibrillation (AF), Non Alcholic Fatty Liver Disease, Sarcopenia, Pericardium
    View official trial listing →
  • Not yet recruiting NCT NCT07588984

    GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study

    Noom Inc. 2310 participants Est. completion 2029-05 1 site
    Cardiovascular disease Other conditions: Obesity & Overweight, Weight Loss, Preventative Health, Body Weight
    View official trial listing →
  • Not yet recruiting NCT NCT07605247

    Tirzepatide in the Treatment of Endometrial Cancer

    Not yet reported Rutgers, The State University of New Jersey 30 participants Est. completion 2028-01 Stand-alone
    Other conditions: Endometrial Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07609160

    Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals

    Not yet reported Acibadem University 108 participants Est. completion 2028-01-01 Stand-alone
    Type 2 diabetes Other conditions: Obesity, Sarcopenia
    View official trial listing →
  • Completed NCT NCT07619508

    Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.

    Brigham and Women's Hospital 100000 participants Est. completion 2026-06-01 1 site
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07622992

    Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery

    Mario Musella MD 96 participants Est. completion 2029-12-01 1 site Stand-alone
    Other conditions: Obesity (BMI > 35) and Diabetes Mellitus, Obesity (BMI > 35) and Dyslipemia, Obesity (BMI > 35) and High Blood Pressure
    View official trial listing →
  • Not yet recruiting NCT NCT07630454

    Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF

    Not yet reported Yunlong Wang 602 participants Est. completion 2029-12-01 1 site Stand-alone
    Heart failure Other conditions: Atrial Fibrillation, Tirzepatide
    View official trial listing →
  • Not yet recruiting NCT NCT07635953

    New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes

    Not yet reported Sun Yat-sen University 296 participants Est. completion 2031-07-01 1 site Stand-alone
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT07638592

    Tirzepatide-Based Prehabilitation Before Elective Ventral and Incisional Hernia Repair in Patients With Obesity

    Azienda Sanitaria Locale Napoli 2 Nord 91 participants Est. completion 2026-06-01 1 site
    Other conditions: Obese Adults, Hernia Abdominal Wall, Prehabilitation
    View official trial listing →
  • Enrolling by invitation NCT NCT07640139

    Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes

    Indiana University 125000 participants Est. completion 2029-12-31 1 site
    Other conditions: Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07668765

    GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity

    Gazi University 100 participants Est. completion 2027-05 1 site
    Other conditions: Morbid Obesity, Anorectal Diseases, Drug-Related Side Effects and Adverse Reactions, Constipation, Diarrhea
    View official trial listing →
  • Not yet recruiting NCT NCT07671248

    Tirzepatide in the Treatment of Cannabis Use Disorder

    Not yet reported McMaster University 15 participants Est. completion 2028-07-31 1 site Stand-alone
    Other conditions: Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
    View official trial listing →
  • Not yet recruiting NCT NCT07671391

    A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants

    Not yet reported Shanghai Zhongshan Hospital 60 participants Est. completion 2027-12 Stand-alone
    Other conditions: Obesity Adult Onset
    View official trial listing →
  • Not yet recruiting NCT NCT07676331

    Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial

    Not yet reported Universitaire Ziekenhuizen KU Leuven 168 participants Est. completion 2028-05-01
    Other conditions: Hormone-receptor-positive Breast Cancer, Early Breast Cancer
    View official trial listing →
  • Completed NCT NCT07677865

    GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

    West China Hospital 213891 participants Est. completion 2026-06-24 1 site
    Type 2 diabetes Other conditions: Alzheimer Disease, Obesity & Overweight
    View official trial listing →
  • Active, not recruiting NCT NCT07685834

    Evaluation of Facial and Neck Skin Laxity With SofWave Treatment in Adults Initiating Tirzepatide for Weight Loss

    Not yet reported Sofwave Medical LTD 30 participants Est. completion 2027-03-01 1 site
    Other conditions: Lax Skin
    View official trial listing →
  • Enrolling by invitation NCT NCT07693608

    An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder

    Not yet reported University of Texas Southwestern Medical Center 45 participants Est. completion 2030-03-01 1 site Stand-alone
    Other conditions: Obesity, Methamphetamine Use Disorder, Cocaine Use Disorder, Stimulant Use Disorders
    View official trial listing →
  • Not yet recruiting NCT NCT07697391

    AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes

    Not yet reported The First Affiliated Hospital of Anhui Medical University 285 participants Est. completion 2028-01-31 2 sites
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07700030

    High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)

    Not yet reported NYU Langone Health 32 participants Est. completion 2027-12 1 site
    Other conditions: Weight Loss
    View official trial listing →
  • Completed NCT NCT07701005

    Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity

    Goztepe Prof Dr Suleyman Yalcın City Hospital 154 participants Est. completion 2026-04-15 1 site
    Other conditions: Steatosis of Liver, Metabolic Liver Injury, Obesity, Overweight, Insulin Resistance
    View official trial listing →
  • Not yet recruiting NCT NCT07706088

    Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy

    Not yet reported Post Graduate Institute of Medical Education and Research, Chandigarh 40 participants Est. completion 2028-07-01 Stand-alone
    Other conditions: Neuropathy, Small Fiber, Diabete Mellitus
    View official trial listing →
  • Enrolling by invitation NCT NCT07707778

    Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV

    Not yet reported National Taiwan University Clinical Trial Center 60 participants Est. completion 2027-12 1 site Stand-alone
    MASLDMetabolic syndrome Other conditions: Human Immunodeficiency Virus (HIV), Dyslipidaemia, Diabetes Mellitus, Obesity & Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07715929

    Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients

    Not yet reported Yunlong Wang 710 participants Est. completion 2029-12-30 Stand-alone
    Other conditions: Atrial Fibrillation, Obesity & Overweight, Catheter Ablation
    View official trial listing →
  • Not yet recruiting NCT NCT07720466

    Salivary Function and Dental Changes During GLP-1 Therapy

    Bilecik Seyh Edebali Universitesi 40 participants Est. completion 2027-03-17 1 site
    Other conditions: Obesity, Dental Erosion, Saliva Collection, Saliva Altered
    View official trial listing →
  • Not yet recruiting NCT NCT07728318

    Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients

    Not yet reported Akhtar Saeed Medical and Dental College 52 participants Est. completion 2027-05-12 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07728812

    Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy

    Not yet reported Phenomix Sciences 424 participants Est. completion 2029-01-01 Stand-alone
    Other conditions: Obesity & Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07734792

    Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial

    Not yet reported, Not yet reported yifang zhu 430 participants Est. completion 2028-07-31 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Not yet recruiting NCT NCT07734870

    Tirzepatide for Treatment of CCCA

    Not yet reported Johns Hopkins University 20 participants Est. completion 2028-05-25 2 sites Stand-alone
    Other conditions: Central Centrifugal Cicatricial Alopecia (CCCA)
    View official trial listing →
  • Not yet recruiting NCT NCT07738276

    Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity

    Not yet reported Shahid Beheshti University of Medical Sciences 60 participants Est. completion 2027-12-22 Stand-alone
    Heart failure Other conditions: Obesity & Overweight, Tirzepatide
    View official trial listing →
  • Not yet recruiting NCT NCT07747805

    GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD

    Not yet reported The Cleveland Clinic 30 participants Est. completion 2029-08-15 1 site
    Other conditions: COPD, Obesity & Overweight, Sarcopenia
    View official trial listing →
  • Not yet recruiting NCT NCT07756359

    Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)

    Not yet reported University of North Carolina, Chapel Hill 20 participants Est. completion 2027-09 5 sites Stand-alone
    Other conditions: Pouch, Ileal, Pouches, Ileoanal, Bowel Diseases, Inflammatory
    View official trial listing →
  • Not yet recruiting NCT NCT07758231

    Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics

    Not yet reported University of Wisconsin, Madison 5 participants Est. completion 2027-03 1 site Stand-alone
    Other conditions: GLP-1, Alcohol
    View official trial listing →
  • Not yet recruiting NCT NCT07760532

    Comparing Facial Aging Between Identical Twins With 3D Imaging

    Ponsky Facial Aesthetics And Plastic Surgery, Llc 200 participants Est. completion 2026-09 1 site
    Other conditions: Facial Skin Aging, Facial Volume Loss, Wrinkle Appearance
    View official trial listing →
  • Not yet recruiting NCT NCT07777575

    Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide

    Not yet reported Technical University of Munich 150 participants Est. completion 2027-05-31 1 site Stand-alone
    Other conditions: Obesity (BMI>30)
    View official trial listing →
  • Not yet recruiting NCT NCT07782359

    Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib

    Not yet reported University of Chicago 30 participants Est. completion 2030-06 1 site Stand-alone
    Other conditions: Lung Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07787936

    GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry

    Miedziowe Centrum Zdrowia SA 150 participants Est. completion 2033-01-01 1 site
    Heart failure Other conditions: Obesity, Pulmonary Hypertension, Iron Deficiency
    View official trial listing →
  • Not yet recruiting NCT NCT07796477

    A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin

    Not yet reported CSPC Ouyi Pharmaceutical Co., Ltd. 240 participants Est. completion 2027-10-19 1 site
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07803744

    A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity

    Not yet reported Eli Lilly and Company 18 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Diabetes Mellitus, Type 1, Overweight, Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07809568

    Real-World Outcomes of Tirzepatide in Pakistani Adults With Obesity, Prediabetes, and Type 2 Diabetes

    Universiti Sains Malaysia 330 participants Est. completion 2028-03-31 9 sites
    PrediabetesType 2 diabetes Other conditions: Obesity & Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07811895

    Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo Transfer

    Not yet reported RenJi Hospital 1510 participants Est. completion 2030-12 1 site Stand-alone
    Other conditions: Tirzepatide, Frozen Embryo Transfer, Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07812636

    Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer

    Not yet reported Milton S. Hershey Medical Center 15 participants Est. completion 2028-08-01 1 site Stand-alone
    Other conditions: Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia, Metabolic Comorbidities
    View official trial listing →
Efficacy history
17.8%

Placebo-adjusted weight loss · 72 weeks

Adults with obesity or overweight, without type 2 diabetes

Trial: SURMOUNT-1 (Phase 3)

Source →

Results from different trials are not directly comparable — populations, timepoints, and measurement methods differ between studies.

Safety

Most common adverse events were gastrointestinal (nausea, diarrhea, constipation), generally mild-to-moderate and dose-dependent, consistent with the GLP-1/GIP class.

Source →
Sources

Also known as: Tirzepatide, LY3298176, Zepbound, Mounjaro, Tirzepatide as an adjunct to lifestyle intervention, Microdose tirzepatide

Related On The Pen coverage

Latest stories

The Weekly Dose & livestreams

Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.